NCT02515097View on ClinicalTrials.gov

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

November 5, 2015

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions
Plaque Psoriasis
Interventions
DRUG

IDP-122 Lotion

Medicated topical lotion

DRUG

IDP-122 Vehicle Lotion

Vehicle topical lotion with no active ingredient

Trial Locations (15)

10001

Valeant Site 04, New York

11790

Valeant Site 12, Stony Brook

27260

Valeant Site 05, High Point

33424

Valeant Site 02, Boynton Beach

33603

Valeant Site 1, Tampa

33755

Valeant Site 10, Clearwater

37901

Valeant Site 11, Knoxville

46168

Valeant Site 07, Plainfield

55421

Valeant Site 08, Fridley

66051

Valeant Site 15, Olathe

68022

Valeant Site 13, Omaha

77001

Valeant Site 03, Houston

78201

Valeant Site 09, San Antonio

84081

Valeant Site 06, West Jordan

92701

Valeant Site 14, Santa Ana

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02515097 - Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis | Biotech Hunter | Biotech Hunter